Wolverine Trading’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Wolverine Trading’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,600	Closed	-$270K	–	5552
2024 Q2	$270K	Sell	6,600 -900	-12%	-$37.5K	﹤0.01%	3517
2024 Q1	$317K	Sell	7,500 -4,900	-40%	-$206K	﹤0.01%	3295
2023 Q4	$526K	Buy	+12,400	New	+$356K	﹤0.01%	2905
2023 Q2	–	Sell	-26,900	Closed	-$645K	–	5148
2023 Q1	$645K	Buy	26,900 +15,300	+132%	+$449K	﹤0.01%	2277
2022 Q4	$366K	Buy	+11,600	New	+$327K	﹤0.01%	2600

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Wolverine Trading's CERE Position: Q3 2024 in Review

Wolverine Trading sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 11,198 shares — an estimated $458K sold.

Wolverine Trading first reported a position in CERE in Q1 2023 and held it in 4 quarters. The position peaked at $669K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Wolverine Trading reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Wolverine Trading sold 11,198 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $458K.
Wolverine Trading first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
Wolverine Trading's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $669K in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.